Improving response to stroke treatment with an antibody drug
Part of Brain & nervous system, Heart & circulation clinical trials.
This Phase 2 trial tests an antibody treatment (TS23) given to people with a suspected acute ischemic stroke to improve how well they respond to stroke care. You may qualify if your stroke scan shows the right pattern of injured brain tissue and if the study drug can be given within a short time window after symptoms start.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a suspected anterior circulation acute ischemic stroke (a type of stroke affecting the front brain arteries)
- Your NIH Stroke Scale score is 4 or higher before randomization, and if it’s 4–5 it must cause a clearly disabling problem
- Your brain scans must look favorable: CT or MRI shows a low enough “core” area and a larger at-risk area (“penumbra”), with specific mismatch measurements
- You can receive the study drug within 4.5 to 24 hours after stroke symptoms started (or last known well)
- You can receive the study drug within 120 minutes after the qualifying perfusion scan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication (bevifibatide) to see which dose works best for people having an ischemic stroke who cannot get standard treatments like clot-busting drugs or a procedure to remove the clot. It aims to improve recovery by stopping clots from getting worse.
This trial tests whether an investigational study drug can improve outcomes after an acute ischemic stroke (a stroke caused by blocked blood flow). You may be eligible if you are able to start treatment quickly after symptom onset and have a moderate stroke severity on a standard stroke exam.
This trial tests if the clot-busting drug tenecteplase can help people with a moderate to severe stroke when given 24 to 72 hours after symptoms began. It aims to see if this later treatment window can improve recovery and reduce disability.
This trial tests whether giving a clot-busting drug called tenecteplase directly into the blocked blood vessel in the brain can help people with a medium-sized vessel occlusion stroke. The drug may help restore blood flow and reduce disability, and it is given within 24 hours of symptom onset.
This trial tests an experimental drug given by IV to help people recover arm and leg movement after a severe stroke. It may help improve recovery in the early weeks after a stroke.
This trial tests if a procedure to remove a large blood clot from the brain (called a thrombectomy) can help people with severe strokes who have a large damaged area. It is for people who can be treated within 24 hours of their stroke starting.
Hear when a new Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.